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IV LIDOCAINE: A SECOND LINE DRUG THERAPY FOR
PEDIATRIC CONVULSIVE STATUS EPILEPTICUS?
R. Fallah    MD
Abstract:
Objective
Refractory convulsive Status Epilepticus (SE) which does not respond to first
line drugs (benzodiazepines, phenytoin and phenobarbital) heralds an
emergency condition in pediatric neurology which can cause irreparable
brain damage. There is no consensus on the choice of drug treatment for
refractory generalized convulsive status epilepticus in children. Lidocaine
is a valuable forgotten antiepileptic agent with favorable properties which
include prompt responses, less alteration of consciousness, and fewer adverse
effects such as respiratory depression.
Materials & Methods
In a retrospective study conducted to  investigate clinical  efficacy and safety
of intravenous  lidocaine in treating refractory generalized  convulsive  SE
of children, the medical records of  13 patients admitted to the Shaheed
Sadoughi Hospital of Yazd between 2003 and  2005 and treated  with
intravenous lidocaine,  were reviewed.
Results
13 patients, 7 girls and 6 boys (average age 3 years, SD=2.7years) were
treated with lidocaine. Neurodevelopmental delay was seen in 38.5 %, and
in 46.2% of them EEG and neuroimaging abnormalities   were observed.
Seizures ceased in eight patients (61/5 %), without any undesirable side
effects. Two patients had to be intubated because of non-responsiveness to
lidocaine, and other treatments were begun .Mean duration of ICU stay
was 4.77 days, SD=3days.
Conclusion
It is recommended that lidocaine be used as a second-line, anticonvulsive
drug in the treatment of status epilepticus, especially when faced with
unavailability of appropriate respiratory care and intubation equipment.
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Status epilepticus (SE), defined as a seizure that persists for a duration long
enough, or is repeated frequently enough, to produce a fixed and enduring epileptic
condition lasting 30 minutes or longer, is a common neurologic medical
emergency(1), of which generalized convulsive SE is the most common and
dangerous type. SE occurs more frequently in young children and elderly adults,
although patients of all ages may experience prolonged seizures (2). It is estimated
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that this life-threatening condition occurs in 1.3% to 16%
of all epileptic children and in some patients presents as
the initial seizure.(3) Correct management strategy
involves prompt control of seizures and treatment of the
underlying etiology.
 The morbidity and mortality of status epilepticus are
significant and directly dependent upon availability of
prompt and appropriate medical therapy; the sequelae
and neurocognitive deficits are particularly pronounced
and potentially fatal in children when the condition
progresses beyond 30 to 60 minutes. Refractory status
epilepticus is defined as seizures that are ongoing, despite
the use of two first-line drugs, usually a benzodiazepine
plus either phenytoin or phenobarbital, or seizures that
continue for more than 60-90 minutes in spite of adequate
treatment(4,5,6). All these patients must be managed in
a pediatric ICU, with aggressive monitoring of their
hemodynamic and respiratory status. There is no
consensus on the choice of drug treatment for refractory
generalized convulsive status epilepticus in children. If
cessation of seizures cannot be achieved, other therapeutic
strategies may have to be used  such as  induction of
barbituric coma with thiopental, general anesthesia using
propofol(7), diazepam drip(8,9), buccal, nasal  or
continuous  infusion  of midazolam(10,11,12)  and
intravenous valproate(13,14) .
Use of these modalities, however, may be associated
with respiratory depression needing mechanical ventilation
and hypotension requiring vasopressor support and
invasive hemodynamic monitoring.
Lidocaine has many pharmacologic attributes such as
antiarrhythmic, local anesthetic and antiepileptic
properties; 1 - 2 mg/kg intravenously, once or twice, and
if necessary, followed by continuous infusion at 2 - 4
mg/kg/hour is one of the second-line drugs in treatment
of  SE(15). The properties of this  drug effective in  SE
 treatment include prompt responses, less alteration of
consciousness, and fewer adverse effects  such  as  less
respiratory depression(16). The basic mechanisms of
lidocaine as an antiepileptic are thought to be analogous
to  its local  anesthetic action; it has a specific membrane
sealing or stabilizing effect on the CNS that restricts the
movement of sodium and potassium across the membrane,
thereby decreasing membrane excitability(17).
Pascual et al suggested that lidocaine may be used as a
first–line drug, as a diazepam substitute, in patients in
whom respiratory or consciousness depression is
undesirable and in those with no response to intravenous
diazepam. The absence of response to lidocaine   indicates
SE is resistant to treatment and  has poor prognosis(18).
Aggarwal et al document lidocaine as a valuable drug,
forgotten in the emergency department(19).
Evidence of lidocaine efficacy has been demonstrated in
many clinical studies, most of which were case reports
or were performed on a limited number of patients(less
than 10).
The purpose of this retrospective study  was to  investigate
the clinical  efficacy and safety of  intravenous  lidocaine
in controlling refractory  generalized  convulsive  SE in
children admitted to the Shaheed  Sadoughi Hospital of
Yazd .
Materials and Methods
In  a retrospective study, medical  records  of all
generalized  convulsive  status epilepticus of  children
treated with intravenous lidocaine  between 2003 and
2005   in Yazd  Shaheed Sadoughi Hospital reviewed.
Inclusion criteria: No history of liver or kidney
dysfunction- past or current-, no hypotension, cardiac
arrhythmia  or block and electrolyte  abnormality; a first
time occurrence of status epilepticus; BUN, Cr, sodium,
potassium, total calcium, and glucose values within
normal limits to exclude electrolyte abnormalities and
hypoglycemia as causes of seizures; admission to the
ICU for aggressive cardiac monitoring
Lidocaine  was used as a second–line drug, because of
lack of seizure-response to benzodiazepines plus either
phenytoin or Phenobarbital.
Lidocaine treatment   protocol:
Initial dose of 1 mg/Kg was given intravenously at a rate
of  25 mg/min. If no response occurred or seizures
recurred, a second bolus dose of 1 mg/Kg was infused.
If seizures did not  stop within  15 minutes following the
second  dose, continuous  lidocaine  infusion  of 1
mg/Kg/h  was  used  and  increased  for  1 mg/Kg/h every
15 minutes until control of  seizures or maximum dose
of 5 mg/Kg/h. If the drug was effective in control of
seizures, the same dose would be repeated for 12 hours
and then decreased 0.5 mg/kg/hour until cessation of
seizures, when the treatment would be considered
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effective. ECG, blood pressure, and oxygen saturation
were continuously monitored to detect any cardiovascular
complications. Serum lidocaine concentration was not
measured. Lidocaine was not administered to patients
with known or suspected cardiac diseases.
If seizures did not cease with maximum dose of drug
infusion drip, it was regarded as being ineffective and
unsuccessful, and hence was discontinued, and a
benzodiazepines or pentobarbital drip was introduced.
Data were gathered from the medical records of the
pediatric ICU. All information on variables such as age,
sex, neuroimaging and EEG findings, concomitant fever,
neurodevelopmental delay, adverse effects (hypotension,
arrhythmia, respiratory depression needing intubation
and mechanical ventilation, acidosis, hypothermia,
hypoxia), seizure control and length of stay in the ICU
were carefully recorded. The data were analyzed using
SPSS 13   statistical software. P values< 0.05 were
considered statistically significant. Written informed
consent was obtained from subject's parents.
Results
In this retrospective study conducted to determine the
efficacy and safety of intravenous lidocaine in treating
seizures caused by refractory generalized convulsive
status epilepticus, the ages of  children ranged from one
month to 9 years( mean age 3 years and SD=2.7 years).
Clinical and Para clinical characteristics of patients are
presented in Table 1.
In eight  of 13 patients( 61/5 %), lidocaine  was  effective
 in controlling seizure; in three patients, seizures  stopped
with the initial dose of  1 mg/Kg  and in another three
with  second bolus dose of 1 mg/Kg;  in one this was
with infusion  of 1 mg/Kg/h and in  another with  2
mg/Kg/h .
Etiology of SE and response to treatment of patients are
showed in Table 2. No undesirable side effects
(paraclinical or clinical) were observed in patients.
Two patients had to be intubated because of non-
responsiveness to lidocaine; they were treated with other
drugs. Duration of stay in the ICU ranged between 1 to
11 days (mean 4.77, SD=3.03).
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Discussion
The purpose of this retrospective study was to investigate
intravenous lidocaine efficacy and safety in refractory
convulsive SE of children. According to the results of
the study the drug was effective in   61.5 % of patients.
Other similar studies have shown a response rate ranging
from 35.8 to 100% (15,16,20,21,22).  One possible
explanation for this discrepancy is the small number of
our patients. Further studies need to be carried to confirm
the efficacy of intravenous lidocaine in treating refractory
status epilepticus.
The results of this study  indicate  that  intubation and
mechanical ventilation  were  not needed in lidocaine
use, which is in agreement with recommendations of
other studies that recommend use of lidocaine  in the
management of SE of patients in whom respiratory
depression is undesirable  (18) or management of
respiratory depression is not possible. Considering the
fact that no alteration of consciousness and respiration
occurred, the lidocaine treatment was cost-effective since
cessation of seizures without side effects shortened the
duration of ICU stay. Our results which show no
occurrence of undesirable effects are in agreement with
those of other studies(16,20,23,24).
Walker and Slovis recommended lidocaine before
barbiturate coma in SE treatment, which agrees with
observations of the current study(25).
The initial bolus doses of lidocaine were effective in six
of eight   patients in whom SE was controlled, indicating
that lidocaine is a rapid acting anticonvulsant, useful in
the short term management of SE.
 One limitation of this study was lack of video-EEG
monitoring and hence our inability to identify/recognize
electrographic seizures cessation.
We conclude that lidocaine, based on its prompt
effectiveness and low risk of side effects, can be used as
a second-line, anti-convulsive drug in status epilepticus,
especially for patients with chronic respiratory disease
or in those having severe disability and respiratory
impairement .
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